Company: ZVRA
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001628280-25-039967
Chunk: 120

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part I, Item 8
Chunk 120
---
 evaluating the impact that this guidance will have on the presentation of its financial statements and accompanying notes.

C.    Segment Information

Zevra manages its business activities on a consolidated basis and operates as a single operating segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. The Company primarily derives its revenue from reimbursements received from product sales of MIPLYFFA and OLPRUVA, reimbursements received under the French AC, and royalties or net sales milestone payments generated under the AZSTARYS License Agreement. The accounting policies of the segment are the same as those described in Note B.Zevra's CODM is the Company's Chief Executive Officer, Neil F. McFarlane. The CODM uses net income (loss), as reported in the Company's unaudited condensed consolidated statements of operations, in evaluating performance of its segment and determining how to allocate resources of the Company as a whole, including investing in its research and development, commercialization efforts, and acquisition strategy. The CODM does not review assets in evaluating the results of the segment, and, therefore, such information is not presented.

15

The following table presents the operating results of the Company's segment for the three and six months ended June 30, 2025, and 2024:Three months ended June 30,Six months ended June 30,2025202420252024Total revenues$25,881 $4,449 $46,282 $7,874 Less significant segment expenses:Research and development directly identified to programs2,339 6,242 4,700 13,453 Research and development not directly identified to programs1,094 4,279 1,991 9,345 Selling, general and administrative directly identified to programs6,439 3,834 14,000 7,696 Selling, general and administrative not directly identified to programs14,343 8,770 26,327 14,839 Other segment items:Impairment of intangible assets58,710 — 58,710 — Income tax expense2,199 70 3,381 — Interest income(2,257)(705)(2,975)(1,467)Depreciation and amortization expense1,651 1,562 3,300 3,124 Interest expense2,009 2,110 3,978 2,845 Other income,